drugset / Trial / NCT00056654
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.
Timeline
- Start
- 2003-03
- Primary completion
- 2004-07
- Completion
- 2004-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 45 mg | Intramuscular |